2020 American Society of Hematology Virtual Annual Meeting *

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!

Share

Program Content

10 Capsule Summary Slidesets

Activities

Magrolimab + Aza in AML
Phase Ib Efficacy, Safety of Anti-CD47 Antibody Magrolimab + Azacitidine in Untreated AML
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

Expires: December 06, 2021

Gilteritinib in ND AML
Phase I Study of Gilteritinib Combined With Induction/Consolidation Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Final Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

Expires: December 06, 2021

QUAZAR AML-001
Phase III QUAZAR AML-001: Analyses of CC-486 (Oral Azacitidine) vs Placebo as Maintenance Therapy in AML After CR/CRi
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

OPTIC Interim Analysis
Randomized Phase II OPTIC Trial of 3 Starting Doses of Ponatinib in Patients With CP-CML: Analysis by Mutation Status and Line of Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Hyper-CVAD + Blinatumomab in B-Cell ALL
Phase II Study of Hyper-CVAD + Blinatumomab in Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

QUAZAR AML-001: MRD
QUAZAR AML-001 Phase III Trial of Oral AZA (CC-486) vs Placebo as Maintenance Therapy in AML After First Remission: Analyses by MRD Status
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

ASCEMBL
ASCEMBL: Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥ 2 TKIs
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Ponatinib After Sec-Gen TKI
Ponatinib After Progression on Second-Generation TKI Therapy in Chronic-Phase Chronic Myeloid Leukemia: Combined Analysis of PACE and OPTIC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Flotetuzumab in AML
Phase I/II Trial of Flotetuzumab as Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Asciminib in <i>T315I</i> CML
Updated Analysis of Phase I Trial of Asciminib, a First-in-Class STAMP Inhibitor, in Patients With Previously Treated BCR-ABL1 T315I–Mutated CML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

Activities

Expert Analysis
Key Studies in Leukemias: Independent Conference Coverage of ASH 2020
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 12, 2021

Expires: February 11, 2022

Podcast
Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2021

Expires: February 25, 2022

ClinicalThought
Expert Selections From ASH 2020: Acute and Chronic Myeloid Leukemias
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: March 03, 2021

Expires: March 02, 2022

15 Capsule Summary Slidesets

Activities

Liso-cel in R/R MCL
TRANSCEND NHL 001: R/R MCL Cohort of Phase I Study of Lisocabtagene Maraleucel
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

Parsaclisib in R/R MZL
CITADEL-204 Phase II Trial of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed/Refractory Marginal Zone Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

Expires: December 07, 2021

Liso-cel/Ibrut in CLL/SLL
TRANSCEND CLL 004: Phase I Results With Lisocabtagene Maraleucel + Ibrutinib in Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

Odronextamab in B-NHL
Phase I Study of Odronextamab, a Novel Bispecific Antibody Targeting CD3 and CD20, for Patients With Heavily Pretreated B-Cell NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Acala in CLL: CV Events
Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Tazemetostat in R/R FL
Predictors of Response to Third-Line Tazemetostat in Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

Ibrut + Ven for CLL
CAPTIVATE: Updated Results From the Phase II Trial of First-line Ibrutinib Plus Venetoclax for CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

cHL: Initial BV for Older Pts
SGN35-015: Phase II Study of Frontline Brentuximab Vedotin ± Second Agent for Older Patients With cHL Ineligible for Standard CT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Mosunetuzumab in R/R FL
Phase I Trial of Mosunetuzumab Bispecific Antibody in Multiply Relapsed Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Phase Ib ACE-CL-003 Trial
Phase Ib ACE-CL-003: Acalabrutinib Combined With Venetoclax and Obinutuzumab or Rituximab in Treatment-Naive or Relapsed/Refractory CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Phase I/II BRUIN Trial
Phase I/II BRUIN Trial of LOXO-305 in Previously Treated Patients With CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

VenR for R/R CLL: 5-Yr FU
MURANO 5-Yr Analysis: Fixed-Duration Venetoclax + Rituximab vs Bendamustine + Rituximab in R/R CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

Umbralisib for R/R iNHL
UNITY-NHL: Umbralisib Monotherapy in Patients With R/R Indolent NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

CLL: Umbralisib/Ublituximab
UNITY-CLL: Phase III Trial of Umbralisib + Ublituximab vs Obinutuzumab + Chlorambucil in Patients With CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

ZUMA-5
ZUMA-5: Phase II Study of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Activities

Expert Analysis
Key Studies in Lymphomas: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2021

Expires: February 25, 2022

ClinicalThought
Expert Selections From ASH 2020: Lymphomas/CLL
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2021

Expires: March 10, 2022

Podcast
Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 26, 2021

Expires: March 25, 2022

8 Capsule Summary Slidesets

Activities

CPI-0610 + RUX in MF
MANIFEST: Novel BET Inhibitor, CPI-0610, Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis Patients
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

HSCT in Older MDS Pts
BMT CTN 1102: RIC Allogeneic HSCT vs Non-HSCT Therapy in Patients 50-75 Yrs With Higher-risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Imetelstat in MF
Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

5-Yr RopegIFN in PV
CONTINUATION-PV: 5-Yr Results of Ropeginterferon α-2b in Polycythemia Vera
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

Pevonedistat/AZA in Higher-Risk MDS
Randomized Phase II Study of Pevonedistat Plus Azacitidine vs Azacitidine: Post Hoc Analysis in Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Roxadustat in LR-MDS
Oral Roxadustat in Anemia Secondary to Lower-Risk MDS: 1-Yr Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

DACOTA DEC vs HY in CMML
DACOTA Phase III Study of Decitabine vs Hydroxyurea for Advanced Proliferative CMML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Luspatercept in MF Anemia
Phase II Study of Luspatercept in RBC Transfusion-Dependent Patients With Myelofibrosis-Associated Anemia: Updated Results
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Activities

Podcast
Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: February 05, 2021

Expires: February 04, 2022

Expert Analysis
Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 16, 2021

Expires: February 15, 2022

ClinicalThought
Expert Selections From ASH 2020: Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 23, 2021

Expires: February 22, 2022

20 Capsule Summary Slidesets

Activities

Phase I AMG 701
First-in-Human Phase I Study of AMG 701: Anti-BCMA Bispecific Antibody in Patients With R/R MM
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

PRIME: P-BCMA-101 in R/R MM
PRIME Phase I/II Trial of P-BCMA-101: Novel CAR T-Cell Therapy in R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

Expires: December 06, 2021

Teclistamab in R/R MM
Phase I Trial: Updated Analysis of BCMA x CD3 Bispecific Antibody Teclistamab (JNJ-64007957) in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

ALGONQUIN Part 1
ALGONQUIN Part 1: Phase I Trial of Belantamab Mafodotin With Pomalidomide/Dexamethasone in Patients With R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

Expires: December 07, 2021

Cevostamab in R/R MM
Cevostamab: Novel FcRH5 x CD3 Bispecific Antibody in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

DREAMM-2: Outcomes by Prior Tx
Phase II DREAMM-2 Study of Belantamab Mafodotin in R/R MM: Outcomes by Number of Prior Therapies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

TOURMALINE-MM2: IRd in ND MM
TOURMALINE-MM2: Oral Ixazomib-Rd vs Placebo-Rd for ASCT-Ineligible Patients With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

GRIFFIN: DVRd vs VRd Maintenance Phase Update
GRIFFIN Maintenance Phase Update: Daratumumab + VRd → Dara-R vs VRd → R Alone for ASCT-Eligible Patients With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

STOMP: Selinexor + Pom/Dex
STOMP Phase I/II Trial: Selinexor/Pomalidomide/Dexamethasone in R/R MM After ≥ 2 Previous Therapies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

APOLLO: SC Dara + Pd vs Pd
Phase III APOLLO: Daratumumab SC + Pom/Dex vs Pom/Dex Alone in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

CRB-402: bb21217 in R/R MM
Updated Analysis of Phase I CRB-402: bb21217 Anti-BCMA CAR T-Cell Therapy in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

Talquetamab in R/R MM
First-in-Human Phase I Trial of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

DREAMM-6: Belamaf + Vd in R/R MM
Phase II DREAMM-6 Arm B: Preliminary Analysis of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

Allogenic Anti-BCMA CAR T-Cell in R/R MM
First-in-Human Phase I UNIVERSAL Trial of Allogeneic CAR T-Cell Therapy With ALLO-715 (Anti-BCMA) and ALLO-647 (Anti-CD52) in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

DREAMM-2: Ocular Safety
DREAMM-2: Ocular Safety During Phase II Study of Belantamab Mafodotin in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

CARTITUDE-1: Cilta-Cel in R/R MM
CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel: BCMA-Directed CAR T-Cell Therapy in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

MEDI2228: R/R MM
BCMA-Targeted ADC MEDI2228: First-in-Human Phase I Study in Patients With R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

REGN5458 in R/R MM
First-in-Human Phase I Study of BCMA x CD3 Bispecific Antibody REGN5458 in Patients With R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Iberdomide + Dd or Vd in R/R MM
Phase I/II Trial of Iberdomide Plus Daratumumab/Dex or Bortezomib/Dex in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

MAIA Update: D-Rd vs Rd
MAIA Updated Analysis: Phase III Study of D-Rd vs Rd for ASCT-Ineligible Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

Activities

ClinicalThought
Expert Selections From ASH 2020: Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2021

Expires: March 07, 2022

Podcast
Expert Insights on Highlights From ASH 2020 on Multiple Myeloma
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2021

Expires: March 11, 2022

Expert Analysis
Key Studies in Myeloma: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2021

Expires: March 21, 2022

10 Capsule Summary Slidesets

Activities

REACH3
REACH3: Phase III Trial of Ruxolitinib vs Best Available Therapy in Steroid-Refractory/Dependent, Chronic GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

HOPE-B: AMT-061 in HEMB
Phase III HOPE-B: Etranacogene Dezaparvovec Gene Therapy in Adults With Severe or Moderately Severe Hemophilia B
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

ITP: 1L MMF + Steroids
FLIGHT: First-line Mycophenolate + Steroids vs Standard Steroid Treatment in Patients With Newly Diagnosed Immune Thrombocytopenia Purpura
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

ROCKstar
ROCKstar Phase II Trial of Daily or Twice-Daily Belumosudil (KD025) in Previously Treated Patients With Chronic GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

BELIEVE: HRQoL Analysis
BELIEVE: HRQoL Outcomes for Patients With Transfusion-Dependent β-Thalassemia Treated With Luspatercept
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

CLIMB THAL-111/SCD-121
CLIMB THAL-111/SCD-121: Phase I/II Studies of CTX001 for Transfusion-Dependent β-Thalassemia and Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

Mitapivat Phase I in SCD
Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

Ph I/II: Rilzabrutinib in ITP
Phase I/II Trial of BTK Inhibitor Rilzabrutinib (PRN1008) for Heavily Pretreated Patients With Immune Thrombocytopenia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

Baricitinib in GVHD
Phase I/II Study of JAK1/2 Inhibitor Baricitinib in Refractory Chronic GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

Itacitinib in GVHD
GRAVITAS-119: Phase I Study of Itacitinib Plus Calcineurin Inhibitors as Prophylaxis for GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Activities

Podcast
Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: February 10, 2021

Expires: February 09, 2022

Expert Analysis
Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2020
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 11, 2021

Expires: February 10, 2022

ClinicalThought
Nonmalignant Hematologic Disorders at ASH 2020: Our Choices for Most Notable Studies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2021

Expires: February 23, 2022

Activities

Key Studies From ASH 2020
An Expert’s Guide to ASH 2020: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 02, 2020

Expires: December 01, 2021

Faculty

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Hanny Al-Samkari, MD

Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

cover img faculity

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

cover img faculity

Amy Esposito, FNP-C

Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

cover img faculity

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

cover img faculity

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

cover img faculity

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.